Specificity of vascular endothelial growth factor treatment for radiation necrosis

Radiother Oncol. 2015 Nov;117(2):382-5. doi: 10.1016/j.radonc.2015.09.004. Epub 2015 Sep 12.

Abstract

Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.

Keywords: Magnetic resonance imaging; Radiation necrosis; Vascular endothelial growth factor.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / pathology*
  • Brain / radiation effects*
  • Disease Models, Animal
  • Female
  • Magnetic Resonance Imaging
  • Mice
  • Mice, Inbred BALB C
  • Necrosis / drug therapy
  • Radiation Injuries, Experimental / therapy*
  • Sensitivity and Specificity
  • Vascular Endothelial Growth Factor A / therapeutic use*

Substances

  • Vascular Endothelial Growth Factor A